BOND03
Brief description of study
This is a Phase 3, open-label, trial designed to evaluate CG0070 in patients with high-grade CIS of the bladder unresponsive to Bacillus-Calmette-Guerin (BCG). The study will enroll up to 110 patients with CIS with or without concomitant high-grade Ta or T1 papillary disease)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
